© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
Uptake of new heart failure drugs slow despite guidelines
EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS
Related Articles
Comparing Efficacy and Safety Between Patients with AF Taking DOACs or Warfarin After a DOAC Failure
April 5, 2017
CLINICAL QUESTION: Is warfarin better as a second-line anticoagulant than another direct oral anticoagulant (DOAC) in patients with atrial-fibrillation-induced ischemic strokes after failure of a...
Beta-Blockers Didn’t Reduce Mortality After Acute MI in Patients with Preserved Ejection Fraction
April 5, 2017
CLINICAL QUESTION: Do beta-blockers still reduce mortality after acute myocardial infarction (MI) in the modern era of faster and better reperfusion strategies? BACKGROUND: Beta-blockers have...
Anticoagulation Safety in Patients with Cirrhosis and AF
April 5, 2017
CLINICAL QUESTION: Do patients with cirrhosis and AF who are treated with anticoagulation have increased adverse safety events compared with patients with cirrhosis and AF who are not treated with...
Coding Corner: Type 1 MI, Type 2 MI, or Non-Ischemic Myocardial Injury
April 5, 2017
An 82-year-old female with a history of hypertension and stage 3 chronic kidney disease (CKD) was admitted with fever, hypotension, and confusion. The workup revealed Escherichia coli bacteremia due...